Replimune Group(NASDAQ) REPL

Replimune Group, Inc. uses viruses to kill tumors and trigger immune systems. These "off-the-shelf" treatments are injected directly into solid tumors. The company creates these therapies for people with various skin cancers.

Fighting Cancer With Viruses

• TUDRIQEV: Approved therapy used with nivolumab to treat adults with unresectable advanced melanoma after previous treatments fail.
• RP2: Experimental candidate engineered to block immune system suppression; currently in clinical trials for eye and liver cancers.
• RP3: Early-stage product candidate designed to activate specific pathways that help T cells attack cancer cells.

Scaling Up the Pipeline

• Received FDA accelerated approval for TUDRIQEV in August 2026 for treating adults with advanced cutaneous melanoma.
• Commenced the IGNYTE-3 Phase 3 confirmatory clinical trial in August 2024 to verify clinical benefits for melanoma patients.
• Implemented a restructuring plan in April 2026 that reduced the total workforce by 55%.
• Secured a clinical trial collaboration with Bristol Myers Squibb for the supply of the anti-PD-1 therapy nivolumab.

Local Attacks and Global Defense

The RPx platform uses a modified strain of the herpes simplex virus to deliver immune-activating proteins to tumors. This technology allows for direct injection to kill cancer cells locally while triggering a system-wide immune response.

Recent Financial Performance

• Net loss was $69.8 million for the three months ended June 30, 2026, compared to $86.7 million year over year.
• Research and development expenses fell to $49.3 million for the three months ended June 30, 2026.
• Selling, general, and administrative expenses were $19.0 million for the three months ended June 30, 2026.
• Cash and short-term investments totaled $195.3 million as of June 30, 2026.
• Company raised $141.0 million in net proceeds from a common stock issuance in August 2026.

The Path to Commercialization

Replimune has transitioned from a research-focused enterprise into a commercial biotechnology company with its first approved therapy. It maintains a development pipeline targeting diverse cancers while managing costs through recent organizational restructuring.